Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 23;21:382. doi: 10.1186/s12890-021-01684-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Longitudinal levels of type VI collagen biomarkers in treated and untreated IPF patients. Serum levels of PRO-C6 (A) and C6M (B) are shown at baseline, six months and 12 months for treated (nintedanib/pirfenidone) (dark blue) and for non-treated (grey); percent change from baseline in PRO-C6 (C) and, C6M (D) at six months and 12 months for treated (dark blue) and non-treated (grey) patients with IPF. Data are presented as geometric mean with 95% CI (error bars) adjusted for age and sex (C and D were also adjusted for PRO-6 or C6M baseline levels). The number of evaluable samples available for analysis at each time point is provided below the graphs. The interaction between timepoint and treatment was not significant for PRO-C6 (P = 0.75), PRO-C6% change (P = 0.60), C6M (P = 0.53) and for C6M percent change (P = 0.77). Significant average contrast across all timepoints between treatment and non-treatment for PRO-C6 and C6M is shown as * (P < 0.05)